Saudi Arabia Cannabidiol Pet Market

The 2025 base-year estimate is USD 0.28 million on a modeled addressable expenditure-equivalent basis. The estimate does not represent a verified pool of SFDA-registered cannabidiol pet-product sales, because no registered product was identified in the public veterinary product assessment. It reflects latent consumer interest, global product price benchmarks, Saudi pet-care expenditure and potential pack-equivalent demand. The resulting figure is intentionally small relative to the Kingdom's USD 275 million pet food market and recognizes that registration, controlled-product classification and import permission determine whether demand can be commercialized.

The base scenario projects the modeled addressable expenditure equivalent to reach USD 1.14 million by 2031, representing a 26.36% CAGR from the 2025 base. Pack-equivalent demand increases from approximately 5,500 units to 17,100 units, while the modeled average selling price rises from USD 50.91 to USD 66.67 per pack. Growth is driven by pet-care premiumization, global category awareness and potential veterinary-channel development. The forecast remains conditional on product classification, safety evidence, registration and lawful distribution rather than assuming general consumer legalization.

The strongest potential profit pool is veterinary-directed oils and tinctures distributed through licensed clinics, pharmacies and specialist importers. These formats support weight-based dosing, higher price realization and more disciplined adverse-event monitoring than mass-market treats. Oils account for the largest global CBD pet product format, while prescription or controlled distribution is structurally more compatible with Saudi veterinary rules. Supporting revenue pools include laboratory testing, regulatory consulting, pharmacovigilance, clinical research and non-CBD functional pet supplements that can monetize existing wellness demand while cannabidiol authorization remains unresolved.

The principal risk is continued absence of a lawful Saudi product pathway for cannabidiol-based veterinary products. Saudi veterinary rules prohibit the import, marketing or circulation of unregistered products, and personal internet or express-mail imports require prior permission. Product developers also face unresolved questions concerning animal safety, dosage, interactions, potency consistency and contaminants. International regulators have not approved general CBD use in animals, reinforcing the likelihood of extensive evidence requirements. A company can therefore incur product-development and market-education costs without obtaining authorization to generate domestic revenue.

Saudi Arabia ranks second among the selected GCC peers by modeled addressable cannabidiol pet expenditure, behind the UAE and ahead of Kuwait, Qatar, Oman and Bahrain. The Kingdom benefits from a larger population, an estimated 1.8 million pets and a USD 275 million pet food market. Its modeled CAGR of 26.36% exceeds Kuwait and Oman but trails the UAE's 29.00% scenario. Across the peer set, the absence of verified registered CBD pet products means regulatory readiness, veterinary infrastructure and evidence capacity are more decisive than conventional retail scale.

Pet humanization is the strongest demand factor because it expands spending from basic nutrition into premium wellness, diagnostics and condition-specific care. Saudi Arabia's pet food market reached USD 275 million in 2024, while pet food imports increased 25% to USD 71.2 million. An estimated 1.8 million pets provide a sizable companion-animal base, particularly in Riyadh, Jeddah and the Eastern Province. These indicators support future demand for calming and mobility solutions, although cannabidiol products must compete with registered botanical, nutritional and pharmaceutical alternatives.